Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020;1(6):434-451.
doi: 10.37349/etat.2020.00028. Epub 2020 Dec 28.

Circulating biomarkers in malignant pleural mesothelioma

Giuseppe Viscardi  1   2 , Davide Di Natale  3 , Morena Fasano  1 , Marta Brambilla  2 , Riccardo Lobefaro  2 , Alessandro De Toma  2 , Giulia Galli  2
Affiliations
Review

Circulating biomarkers in malignant pleural mesothelioma

Giuseppe Viscardi et al. Explor Target Antitumor Ther. 2020.

Abstract

Malignant pleural mesothelioma (MPM) is an aggressive tumor strictly connected to asbestos exposure. Prognosis is dismal as diagnosis commonly occurs in advanced stage. Radiological screenings have not proven to be effective and also pathological diagnosis may be challenging. In the era of precision oncology, validation of robust non-invasive biomarkers for screening of asbestos-exposed individuals, assessment of prognosis and prediction of response to treatments remains an important unmet clinical need. This review provides an overview on current understanding and possible applications of liquid biopsy in MPM, mostly focused on the utility as diagnostic and prognostic test.

Keywords: CTC; Mesothelioma; biomarkers; ctDNA; liquid biopsy; malignant pleural mesothelioma; mesothelin; miRNAs.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Figure 1.
Figure 1.
Circulating biomarkers analysis in malignant pleural mesothelioma
See this image and copyright information in PMC

References

    1. Pelucchi C, Malvezzi M, La Vecchia C, Levi F, Decarli A, Negri E. The Mesothelioma epidemic in Western Europe: an update. Br J Cancer. 2004;90:1022–4. 10.1038/sj.bjc.6601638 - DOI - PMC - PubMed
    1. Viscardi G, Di Liello R, Morgillo F. How I treat malignant pleural mesothelioma. ESMO Open. 2020;4 Suppl 2:e000669. 10.1136/esmoopen-2019-000669 - DOI - PMC - PubMed
    1. Hegmans JP, Hemmes A, Hammad H, Boon L, Hoogsteden HC, Lambrecht BN. Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses. Eur Respir J. 2006;27:1086–95. 10.1183/09031936.06.00135305 - DOI - PubMed
    1. Bueno R, Stawiski EW, Goldstein LD, Durinck S, De Rienzo A, Modrusan Z, et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat Genet. 2016;48:407–16. 10.1038/ng.3520 - DOI - PubMed
    1. Pass HI, Carbone M. Current status of screening for malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg. 2009;21:97–104. 10.1053/j.semtcvs.2009.06.007 - DOI - PubMed

LinkOut - more resources